AAPL322.01-6.20 (-1.89%) ▼|ABBV256.00-4.22 (-1.62%) ▼|ABT109.00+0.21 (+0.19%) ▲|ACN187.09-6.04 (-3.13%) ▼|ADBE268.59-17.16 (-6.01%) ▼|AMAT452.21+16.30 (+3.74%) ▲|AMD471.72+15.56 (+3.41%) ▲|AMGN436.90-7.22 (-1.63%) ▼|AMT175.81-1.94 (-1.09%) ▼|AMZN258.26-0.65 (-0.25%) ▼|AVGO356.28-0.88 (-0.25%) ▼|AXP326.71-3.11 (-0.94%) ▼|BA211.69+1.18 (+0.56%) ▲|BAC62.64-0.08 (-0.13%) ▼|BKNG193.63-1.50 (-0.77%) ▼|BLK1,121.80-4.35 (-0.39%) ▼|BMY66.65-1.44 (-2.11%) ▼|BNY165.23+0.90 (+0.55%) ▲|BRK-B505.99-2.14 (-0.42%) ▼|C137.72-0.42 (-0.30%) ▼|CAT810.20+10.06 (+1.26%) ▲|CL89.04-1.05 (-1.17%) ▼|CMCSA26.51-0.14 (-0.53%) ▼|COF219.19-1.31 (-0.59%) ▼|COP134.48-1.24 (-0.91%) ▼|COST917.72-7.70 (-0.83%) ▼|CRM260.49-3.94 (-1.49%) ▼|CSCO109.30+0.69 (+0.64%) ▲|CVS96.97-0.23 (-0.24%) ▼|CVX208.44-2.88 (-1.36%) ▼|DE695.87+1.46 (+0.21%) ▲|DHR207.45-3.58 (-1.70%) ▼|DIS105.76-1.40 (-1.31%) ▼|DUK120.26-1.14 (-0.94%) ▼|EMR152.49+2.28 (+1.51%) ▲|FDX321.96-2.36 (-0.73%) ▼|GD358.54-7.33 (-2.00%) ▼|GE336.44+2.96 (+0.89%) ▲|GEV941.39-0.46 (-0.05%) ▼|GILD150.41-0.81 (-0.54%) ▼|GM87.45+0.41 (+0.47%) ▲|GOOG336.11-2.97 (-0.87%) ▼|GOOGL339.36-2.90 (-0.85%) ▼|GS1,036.76-1.18 (-0.11%) ▼|HD321.52+3.45 (+1.08%) ▲|HON208.64+1.01 (+0.48%) ▲|IBM234.35-0.36 (-0.15%) ▼|INTC94.71+3.04 (+3.32%) ▲|INTU332.41-11.89 (-3.45%) ▼|ISRG366.92-2.92 (-0.79%) ▼|JNJ275.37-3.07 (-1.10%) ▼|JPM358.04-4.02 (-1.11%) ▼|KO88.04-0.77 (-0.87%) ▼|LIN478.46-3.74 (-0.77%) ▼|LLY1,142.99-16.61 (-1.43%) ▼|LMT524.92-8.03 (-1.51%) ▼|LOW205.05+3.15 (+1.56%) ▲|LRCX303.28+10.62 (+3.63%) ▲|MA581.09-4.62 (-0.79%) ▼|MCD256.62-3.01 (-1.16%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.32+1.22 (+1.31%) ▲|META615.44+4.76 (+0.78%) ▲|MMM168.37+0.06 (+0.03%) ▲|MO69.00-0.50 (-0.71%) ▼|MRK150.28-2.06 (-1.35%) ▼|MS217.02-0.13 (-0.06%) ▼|MSFT500.11-10.01 (-1.96%) ▼|MU1,003.46+45.30 (+4.73%) ▲|NEE83.42-0.64 (-0.76%) ▼|NFLX78.76-3.92 (-4.74%) ▼|NKE38.57-0.21 (-0.53%) ▼|NOW141.24-4.35 (-2.99%) ▼|NVDA229.89+1.44 (+0.63%) ▲|ORCL156.89+2.85 (+1.85%) ▲|PEP137.85-0.70 (-0.50%) ▼|PFE28.42-0.39 (-1.35%) ▼|PG146.32-0.61 (-0.41%) ▼|PLTR174.25-8.28 (-4.54%) ▼|PM182.65-3.52 (-1.89%) ▼|QCOM167.28-1.29 (-0.77%) ▼|RTX200.65-1.48 (-0.73%) ▼|SBUX104.87-0.95 (-0.90%) ▼|SCHW109.47-0.91 (-0.82%) ▼|SO87.96-0.82 (-0.92%) ▼|SPG210.17-1.35 (-0.64%) ▼|T25.78-0.42 (-1.58%) ▼|TMO612.37-6.06 (-0.98%) ▼|TMUS182.89-5.13 (-2.73%) ▼|TSLA354.76-21.61 (-5.74%) ▼|TXN257.59+3.76 (+1.48%) ▲|UBER76.41+0.45 (+0.59%) ▲|UNH395.68-5.26 (-1.31%) ▼|UNP289.99+0.84 (+0.29%) ▲|UPS102.41-1.10 (-1.06%) ▼|USB63.37-0.17 (-0.26%) ▼|V374.63-4.12 (-1.09%) ▼|VZ50.27-0.33 (-0.64%) ▼|WFC89.82+0.63 (+0.71%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM159.78-2.44 (-1.50%) ▼|AAPL322.01-6.20 (-1.89%) ▼|ABBV256.00-4.22 (-1.62%) ▼|ABT109.00+0.21 (+0.19%) ▲|ACN187.09-6.04 (-3.13%) ▼|ADBE268.59-17.16 (-6.01%) ▼|AMAT452.21+16.30 (+3.74%) ▲|AMD471.72+15.56 (+3.41%) ▲|AMGN436.90-7.22 (-1.63%) ▼|AMT175.81-1.94 (-1.09%) ▼|AMZN258.26-0.65 (-0.25%) ▼|AVGO356.28-0.88 (-0.25%) ▼|AXP326.71-3.11 (-0.94%) ▼|BA211.69+1.18 (+0.56%) ▲|BAC62.64-0.08 (-0.13%) ▼|BKNG193.63-1.50 (-0.77%) ▼|BLK1,121.80-4.35 (-0.39%) ▼|BMY66.65-1.44 (-2.11%) ▼|BNY165.23+0.90 (+0.55%) ▲|BRK-B505.99-2.14 (-0.42%) ▼|C137.72-0.42 (-0.30%) ▼|CAT810.20+10.06 (+1.26%) ▲|CL89.04-1.05 (-1.17%) ▼|CMCSA26.51-0.14 (-0.53%) ▼|COF219.19-1.31 (-0.59%) ▼|COP134.48-1.24 (-0.91%) ▼|COST917.72-7.70 (-0.83%) ▼|CRM260.49-3.94 (-1.49%) ▼|CSCO109.30+0.69 (+0.64%) ▲|CVS96.97-0.23 (-0.24%) ▼|CVX208.44-2.88 (-1.36%) ▼|DE695.87+1.46 (+0.21%) ▲|DHR207.45-3.58 (-1.70%) ▼|DIS105.76-1.40 (-1.31%) ▼|DUK120.26-1.14 (-0.94%) ▼|EMR152.49+2.28 (+1.51%) ▲|FDX321.96-2.36 (-0.73%) ▼|GD358.54-7.33 (-2.00%) ▼|GE336.44+2.96 (+0.89%) ▲|GEV941.39-0.46 (-0.05%) ▼|GILD150.41-0.81 (-0.54%) ▼|GM87.45+0.41 (+0.47%) ▲|GOOG336.11-2.97 (-0.87%) ▼|GOOGL339.36-2.90 (-0.85%) ▼|GS1,036.76-1.18 (-0.11%) ▼|HD321.52+3.45 (+1.08%) ▲|HON208.64+1.01 (+0.48%) ▲|IBM234.35-0.36 (-0.15%) ▼|INTC94.71+3.04 (+3.32%) ▲|INTU332.41-11.89 (-3.45%) ▼|ISRG366.92-2.92 (-0.79%) ▼|JNJ275.37-3.07 (-1.10%) ▼|JPM358.04-4.02 (-1.11%) ▼|KO88.04-0.77 (-0.87%) ▼|LIN478.46-3.74 (-0.77%) ▼|LLY1,142.99-16.61 (-1.43%) ▼|LMT524.92-8.03 (-1.51%) ▼|LOW205.05+3.15 (+1.56%) ▲|LRCX303.28+10.62 (+3.63%) ▲|MA581.09-4.62 (-0.79%) ▼|MCD256.62-3.01 (-1.16%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.32+1.22 (+1.31%) ▲|META615.44+4.76 (+0.78%) ▲|MMM168.37+0.06 (+0.03%) ▲|MO69.00-0.50 (-0.71%) ▼|MRK150.28-2.06 (-1.35%) ▼|MS217.02-0.13 (-0.06%) ▼|MSFT500.11-10.01 (-1.96%) ▼|MU1,003.46+45.30 (+4.73%) ▲|NEE83.42-0.64 (-0.76%) ▼|NFLX78.76-3.92 (-4.74%) ▼|NKE38.57-0.21 (-0.53%) ▼|NOW141.24-4.35 (-2.99%) ▼|NVDA229.89+1.44 (+0.63%) ▲|ORCL156.89+2.85 (+1.85%) ▲|PEP137.85-0.70 (-0.50%) ▼|PFE28.42-0.39 (-1.35%) ▼|PG146.32-0.61 (-0.41%) ▼|PLTR174.25-8.28 (-4.54%) ▼|PM182.65-3.52 (-1.89%) ▼|QCOM167.28-1.29 (-0.77%) ▼|RTX200.65-1.48 (-0.73%) ▼|SBUX104.87-0.95 (-0.90%) ▼|SCHW109.47-0.91 (-0.82%) ▼|SO87.96-0.82 (-0.92%) ▼|SPG210.17-1.35 (-0.64%) ▼|T25.78-0.42 (-1.58%) ▼|TMO612.37-6.06 (-0.98%) ▼|TMUS182.89-5.13 (-2.73%) ▼|TSLA354.76-21.61 (-5.74%) ▼|TXN257.59+3.76 (+1.48%) ▲|UBER76.41+0.45 (+0.59%) ▲|UNH395.68-5.26 (-1.31%) ▼|UNP289.99+0.84 (+0.29%) ▲|UPS102.41-1.10 (-1.06%) ▼|USB63.37-0.17 (-0.26%) ▼|V374.63-4.12 (-1.09%) ▼|VZ50.27-0.33 (-0.64%) ▼|WFC89.82+0.63 (+0.71%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM159.78-2.44 (-1.50%) ▼|
29.8 C
New York
Friday, September 4, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

REPEAT — Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion...

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

APhA Foundation announces 2025 Pinnacle Award recipients

WASHINGTON, Aug. 11, 2025 /PRNewswire/ -- The American Pharmacists Association Foundation today announced the recipients of the 2025 Pinnacle Awards. ...

The Galien Foundation Announces 2025 Prix Galien USA Nominees for “Best Biotechnology Product,” “Best Pharmaceutical Product” and “Best Product for Rare/Orphan Diseases”

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the...

The Dot Corp Achieves ISO 9001:2015 Certification, Reinforcing Leadership in Healthcare Fulfillment and Lab Testing Logistics

IRVINE, Calif., Aug. 11, 2025 /PRNewswire/ -- The Dot Corp. is proud to announce it has earned ISO 9001:2015 certification, further solidifying its position...

Activated Carbon Market to Grow at a CAGR of 8.3% from 2025 to 2032 | SkyQuest Technology Consulting

The activated carbon market is anticipated to expand at a rapid pace due to rising global demand for clean water, and effective wastewater treatment.  WESTFORD,...

Activated Carbon Market to Grow at a CAGR of 8.3% from 2025 to 2032 | SkyQuest Technology Consulting

The activated carbon market is anticipated to expand at a rapid pace due to rising global demand for clean water, and effective wastewater treatment.  WESTFORD,...

REPEAT – Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing

HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced...

AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus

SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead candidate,...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers